The Impact of Young Age for Prognosis by Subtype in Women with Early Breast Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2017 Sep 16

PMID 28912475

Citations 45

Authors

Weibin Lian

Fangmeng Fu

Yuxiang Lin

Minjun Lu

Boyang Chen

Peidong Yang

Bangwei Zeng

Meng Huang

Chuan Wang

Affiliations

Soon will be listed here.

Abstract

Young age (≤40 years) use to be considered an independent risk factor for the prognosis of women with early-stage breast cancer. We conducted a retrospective analysis to investigate this claim in a population of young patients who were stratified by molecular subtype. We identified 2,125 women with stage I to III breast cancer from the Fujian Medical University Union Hospital. Multivariable Cox proportional hazards models were used to analyze the relationship between age groups stratified by molecular subtype and 5-year disease-free survival (DFS), 5-year distant metastasis-free survival (DMFS), and 5-year breast cancer-specific survival (BCSS). Median follow-up time was 77 months. Patients ≤40 years of age presented with a significantly worse 5-year DFS and 5-year DMFS. In stratified analyses, young women with luminal A subtype disease were associated with a worse 5-year DFS, 5-year DMFS, and 5-year BCSS. Women with luminal B (Her2-) tumors showed a decrease in 5-year DFS and 5-year DMFS. Our findings support the hypothesis that young age seems to be an independent risk factor for the prognosis for breast cancer patients with the luminal A and luminal B (Her2-) subtypes but not in those with luminal B (Her2+), Her2 over-expression, and triple-negative disease.

Citing Articles

Development of a breast cancer risk assessment and primary prevention pathway for women aged 30-39 years: Views of UK primary care providers on the role of primary care.

Hindmarch S, Gorman L, Usher-Smith J, Woof V, Howell S, French D PLoS One. 2024; 19(9):e0308638.

PMID: 39269936 PMC: 11398678. DOI: 10.1371/journal.pone.0308638.

Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.

Khoirunnisa S, Suryanegara F, Setiawan D, Postma M, de Jong L PLoS One. 2024; 19(5):e0304483.

PMID: 38787899 PMC: 11125485. DOI: 10.1371/journal.pone.0304483.

KDM7A-DT induces genotoxic stress, tumorigenesis, and progression of p53 missense mutation-associated invasive breast cancer.

Giannakakis A, Tsifintaris M, Gouzouasis V, Ow G, Aau M, Papp C Front Oncol. 2024; 14:1227151.

PMID: 38756663 PMC: 11097164. DOI: 10.3389/fonc.2024.1227151.

Breast cancer insights from Northern Israel: a comprehensive analysis of survival rates among Jewish and Arab women.

Badran O, Campisi-Pinto S, Amna M, Turgeman I, Yosef S, Bar-Sela G Front Oncol. 2024; 14:1337521.

PMID: 38720806 PMC: 11076725. DOI: 10.3389/fonc.2024.1337521.

Imaging Patterns in Breast Cancer for Women Under 40 Years: A Descriptive Cohort Study.

Alhaidary A, Al-Qudimat A, Arabi H, Al-Zoubi R J Epidemiol Glob Health. 2024; 14(1):63-71.

PMID: 38206550 PMC: 11043463. DOI: 10.1007/s44197-023-00169-2.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Kheirelseid E, Boggs J, Curran C, Glynn R, Dooley C, Sweeney K . Younger age as a prognostic indicator in breast cancer: a cohort study. BMC Cancer. 2011; 11:383. PMC: 3184119. DOI: 10.1186/1471-2407-11-383. View

Brinton L, Sherman M, Carreon J, Anderson W . Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst. 2008; 100(22):1643-8. PMC: 2720764. DOI: 10.1093/jnci/djn344. View

Coates A, Winer E, Goldhirsch A, Gelber R, Gnant M, Piccart-Gebhart M . Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; 26(8):1533-46. PMC: 4511219. DOI: 10.1093/annonc/mdv221. View

Keegan T, Press D, Tao L, DeRouen M, Kurian A, Clarke C . Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res. 2013; 15(5):R95. PMC: 3978627. DOI: 10.1186/bcr3556. View

Kim E, Noh W, Han W, Noh D . Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study. World J Surg. 2011; 35(6):1244-53. DOI: 10.1007/s00268-011-1071-1. View

Engstrom M, Opdahl S, Hagen A, Romundstad P, Akslen L, Haugen O . Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat. 2013; 140(3):463-73. PMC: 3742963. DOI: 10.1007/s10549-013-2647-2. View

Azim Jr H, Michiels S, Bedard P, Singhal S, Criscitiello C, Ignatiadis M . Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 2012; 18(5):1341-51. DOI: 10.1158/1078-0432.CCR-11-2599. View

Sheridan W, Scott T, Caroline S, Yvonne Z, Vanessa B, David V . Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?. Breast Cancer Res Treat. 2014; 147(3):617-29. DOI: 10.1007/s10549-014-3125-1. View

10.

Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thurlimann B . Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. PMC: 3755334. DOI: 10.1093/annonc/mdt303. View

11.

Wang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T . Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer. Ann Oncol. 2014; 26(3):523-8. DOI: 10.1093/annonc/mdu559. View

12.

Hershman D, Shao T, Kushi L, Buono D, Tsai W, Fehrenbacher L . Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2010; 126(2):529-37. PMC: 3462663. DOI: 10.1007/s10549-010-1132-4. View

13.

Collins L, Marotti J, Gelber S, Cole K, Ruddy K, Kereakoglow S . Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2011; 131(3):1061-6. DOI: 10.1007/s10549-011-1872-9. View

14.

Zhang Q, Ma B, Kang M . A retrospective comparative study of clinicopathological features between young and elderly women with breast cancer. Int J Clin Exp Med. 2015; 8(4):5869-75. PMC: 4483854. View

15.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua M, Pruneri G . Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol. 2010; 21(10):1974-1981. DOI: 10.1093/annonc/mdq072. View

16.

Regan M, Pagani O, Francis P, Fleming G, Walley B, Kammler R . Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat. 2015; 154(2):275-86. PMC: 4749471. DOI: 10.1007/s10549-015-3612-z. View

17.

Ahn S, Son B, Kim S, Kim S, Jeong J, Ko S . Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. J Clin Oncol. 2007; 25(17):2360-8. DOI: 10.1200/JCO.2006.10.3754. View

18.

Walshe J, Denduluri N, Swain S . Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006; 24(36):5769-79. DOI: 10.1200/JCO.2006.07.2793. View

19.

Hershman D, Kushi L, Shao T, Buono D, Kershenbaum A, Tsai W . Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010; 28(27):4120-8. PMC: 2953970. DOI: 10.1200/JCO.2009.25.9655. View

20.

Kennecke H, Yerushalmi R, Woods R, Chon U Cheang M, Voduc D, Speers C . Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010; 28(20):3271-7. DOI: 10.1200/JCO.2009.25.9820. View